Literature DB >> 7618661

Intubating conditions following 1R CIS, 1'R CIS atracurium (51W89). A comparison with atracurium.

I H Littlejohn1, K Abhay, A el Sayed, C J Broomhead, P Duvaldestin, P J Flynn.   

Abstract

51W89 besylate, a new intermediate acting non-depolarising muscle relaxant, consisting of a single stereo-isomer of the commercial preparation of atracurium has been assessed in respect of intubating conditions during nitrous oxide-propofol-isoflurane anaesthesia. Intubating conditions at 2 min were acceptable in 67% of patients following a dose of 0.1 mg.kg-1 and in 90% of patients following a dose of 0.15 mg.kg-1. Intubating conditions at 1.5 min were acceptable in 76% of patients following a dose of 0.2 mg.kg-1. In comparison, intubating conditions at 2 min were acceptable in 95% of patients following 0.5 mg.kg-1 of atracurium. The intubating conditions at 2 min following a dose of 0.1 mg.kg-1 51W89 besylate were significantly worse than the other three groups (p < 0.05); however, there was no significant differences between the scores in the other three groups. There was no clinical evidence of histamine release in the groups receiving 51W89 besylate compared to two out of the 19 patients who had cutaneous flushing following the administration of atracurium. Our results suggest that 51W89 besylate provides acceptable intubating conditions at 2 min following a dose of 0.15 mg.kg-1 and may prove to be an acceptable alternative to atracurium if studies in progress confirm its greater cardiovascular stability and reduced propensity to release histamine than its parent compound.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618661     DOI: 10.1111/j.1365-2044.1995.tb06038.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  6 in total

Review 1.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  [New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium].

Authors:  T Fuchs-Buder
Journal:  Anaesthesist       Date:  1997-04       Impact factor: 1.041

Review 3.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 4.  Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

Authors:  H M Bryson; D Faulds
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

5.  [Priming technique with cisatracurium Onset time at the laryngeal muscles].

Authors:  J Schmidt; S Albrecht; N Petterich; J Fechner; P Klein; A Irouschek
Journal:  Anaesthesist       Date:  2007-10       Impact factor: 1.041

6.  Pharmacodynamics of cisatracurium in the intensive care unit: an observational study.

Authors:  Eric Dieye; Vincent Minville; Karim Asehnoune; Claude Conil; Bernard Georges; Pierre Cougot; Olivier Fourcade; Jean-Marie Conil
Journal:  Ann Intensive Care       Date:  2014-02-11       Impact factor: 6.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.